Company Contact: John F. DeBernardis, Ph.D., President & CEO
Investor Contact: Ira Weingarten/Steve Chizzik
Media Contact: Jeff Siegel, Monarch Communications
Applied NeuroSolutions, Inc. President and CEO
Interviewed on “Business Talk This Morning” Radio Show
Vernon Hills, IL, August 31, 2005 -
Applied NeuroSolutions, Inc. (OTC BB: APNS, www.appliedneurosolutions.com) today said that an interview with its President and CEO, Dr. John DeBernardis, can be heard on “Business Talk This Morning,” a syndicated radio program that runs on the Business Talk Radio Network.
The interview is expected to air on Thursday, September 1, at approximately 6:30 a.m. EST, on approximately 35 stations across the country. The show can also be heard via the Internet at www.businesstalkradio.net.
Applied NeuroSolutions, Inc. is developing products to diagnose and treat Alzheimer's disease based on a novel hypothesis of AD pathology. In partnership with Dr. Peter Davies and a scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions has developed a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy in more than 3,000 patient samples. There are approximately 2 million new patients worldwide who are candidates for an AD CSF diagnostic test, according to Datamonitor. In the U.S. alone, Datamonitor projects $80 to $160 million annual market potential. The company is also developing a blood serum-based screening test, as well as a new class of therapeutics to treat AD. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets ( USA, France, Germany, Italy, Spain, U.K. and Japan ) according to BioPortfolio, Ltd.
There are currently no FDA-approved diagnostic tests to detect Alzheimer's disease.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.